Literature DB >> 22477792

Dexmedetomidine to control agitation and delirium from toxic ingestions in adolescents.

Joseph D Tobias1.   

Abstract

Dexmedetomidine is an α(2)-adrenergic agonist that is approved by the Food and Drug Administration for the provision of short term (less than 24 hours) sedation of adults during mechanical ventilation. Given its beneficial physiologic effects including sedation and anxiolysis, various applications have been reported in the pediatric-aged patient. We report the use of dexmedetomidine to control the agitation and violent behavior which resulted from the ingestion of illicit drugs in 3 adolescents. The utility of dexmedetomidine in these scenarios is discussed and its potential beneficial effects on cardiovascular and respiratory function are reviewed.

Entities:  

Year:  2010        PMID: 22477792      PMCID: PMC3017407     

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  28 in total

1.  The effect of intravenous dexmedetomidine premedication on the dose requirement of propofol to induce loss of consciousness in patients receiving alfentanil.

Authors:  C J Peden; A H Cloote; N Stratford; C Prys-Roberts
Journal:  Anaesthesia       Date:  2001-05       Impact factor: 6.955

2.  Dexmedetomidine and cardiac arrest.

Authors:  Esperanza Ingersoll-Weng; Gerard R Manecke; Patricia A Thistlethwaite
Journal:  Anesthesiology       Date:  2004-03       Impact factor: 7.892

Review 3.  Ecstasy: pharmacology and neurotoxicity.

Authors:  Jenny Morton
Journal:  Curr Opin Pharmacol       Date:  2005-02       Impact factor: 5.547

Review 4.  Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology.

Authors:  Joseph D Tobias
Journal:  Pediatr Crit Care Med       Date:  2007-03       Impact factor: 3.624

5.  "DXM": a new drug of abuse?

Authors:  S P Nordt
Journal:  Ann Emerg Med       Date:  1998-06       Impact factor: 5.721

Review 6.  The background and chemistry of MDMA.

Authors:  A T Shulgin
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

7.  Contents of "ecstasy".

Authors:  K Wolff; A W Hay; K Sherlock; M Conner
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

8.  Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")

Authors:  J A Henry; K J Jeffreys; S Dawling
Journal:  Lancet       Date:  1992-08-15       Impact factor: 79.321

9.  Alpha2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A-adrenoceptor subtype.

Authors:  Janne Lähdesmäki; Jukka Sallinen; Ewen MacDonald; Jouni Sirviö; Mika Scheinin
Journal:  Neuropharmacology       Date:  2003-06       Impact factor: 5.250

Review 10.  Dextromethorphan. An overview of safety issues.

Authors:  J L Bem; R Peck
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

View more
  4 in total

1.  Dexmedetomidine Infusion to Control Agitation due to Anticholinergic Toxidromes in Adolescents, a Case Series.

Authors:  Samantha W Gee; Ada Lin; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 2.  Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Authors:  Henry A Spiller; Hannah L Hays; Alfred Aleguas
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

3.  Dexmedetomidine as an Adjunct to Treat Anticholinergic Toxidrome in Children.

Authors:  Krista Cowan; Rebecca A Landman; Arun Saini
Journal:  Glob Pediatr Health       Date:  2017-04-24

4.  The Role of Dexmedetomidine in Pediatric Patients Presenting with an Anticholinergic Toxidrome.

Authors:  Mitchell Zekhtser; Erin Carroll; Molly Boyd; Shashikanth Ambati
Journal:  Case Rep Crit Care       Date:  2021-08-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.